Skip Navigation



Rheumatology Advance Access published online on September 1, 2007
Rheumatology, doi:10.1093/rheumatology/kem195
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
46/10/1626-a    most recent
kem195v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Del Porto, F.
Right arrow Articles by D’Amelio, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Del Porto, F.
Right arrow Articles by D’Amelio, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Letter to the Editor

Effects of tumour necrosis factor alpha blockade on lipid profile in active rheumatoid arthritis

F. Del Porto, B. Laganà, I. Nofroni1, F. Tinti2, A. P. Mitterhofer2,* and R. D’Amelio*

"Sapienza" Università di Roma, II Facoltà di Medicina e Chirurgia, Azienda Ospedaliera S.Andrea, Dipartimento di Scienze Mediche; I Facoltà di Medicina e Chirurgia, 1Dipartimento di Medicina Sperimentale and 2Dipartimento di Medicina Clinica.

Correspondence to: Flavia Del Porto, MD, Università ‘La Sapienza’, II Facoltà di Medicina e Chirurgia, Azienda Ospedaliera Sant’Andrea, Dipartimento di Scienze Mediche, Via di Grottarossa 1039, 00189 Roma, Italia. E-mail: flavia.delporto@uniroma1.it

The first 10% of the full text of this article appears below.

SIR, We would like to thank Dr Armstrong for his helpful comment regarding lipid profile behaviour during anti-tumour necrosis factor (TNF)-{alpha} treatment. Such a topic is of increasing interest in the literature, despite lack of long-term definitive supporting evidence [1–4]. Actually, in patients with rheumatoid arthritis (RA) . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?